Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)

Basit Öğe Kaydı
dc.contributor.authorTeomete, Mehmet
dc.contributor.authorCabuk, Devrim
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSeber, Selcuk
dc.contributor.authorOzturk, Ozge Fulya
dc.contributor.authorAver, Birkan
dc.contributor.authorKaraalp, Atila
dc.date.accessioned2024-10-29T17:59:30Z
dc.date.available2024-10-29T17:59:30Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBreast cancer is most frequently diagnosed among women aged 65-74 years and the prevalence of comorbidities in elderly patients with breast cancer is 32.2%. In addition, polypharmacy is quite common in these patients. Understanding the interaction between breast cancer treatment modalities and comorbidities is important, particularly in elderly patients, as comorbidities affect the choice of appropriate treatment and are independent risk factors for survival. A total of three oral cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), palbociclib, ribociclib and abemaciclib, notably prolonged progression-free survival when combined with endocrine therapy (ET), compared with ET alone in patients with advanced breast cancer (ABC). The present review article therefore addressed the safety, tolerability and toxicity of CDK4/6i treatment in ABC management, compiled real-world data on how multiple clinical and pharmacological features may affect the choice of these drugs and provided practical recommendations for clinical approaches. Before starting treatment with CDK4/6i drugs, all ongoing medical conditions should be inventorized and re-graded, and examination should be performed for any additional disease that the patient may not be aware of. It is also important to obtain a detailed history of concomitant drugs, including prescription and over-the-counter drugs, vitamins, supplements and herbal products. In addition, patients should be advised to consult their oncologist before starting any new medication.
dc.description.sponsorshipPfizer
dc.description.sponsorshipThe present review was funded by Pfizer.
dc.identifier.doi10.3892/ol.2024.14278
dc.identifier.issn1792-1074
dc.identifier.issn1792-1082
dc.identifier.issue4en_US
dc.identifier.pmid38385117
dc.identifier.scopus2-s2.0-85185715956
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.3892/ol.2024.14278
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14754
dc.identifier.volume27
dc.identifier.wosWOS:001169395400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpandidos Publ Ltd
dc.relation.ispartofOncology Letters
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectadvanced breast cancer
dc.subjectcomorbidity
dc.subjectcyclin-dependent kinase 4 and 6 inhibitors
dc.subjectsafety
dc.subjecttolerability
dc.subjecttoxicity
dc.titleRecommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu